
Overview
Healthcare apparel brand's Q4 2025 revenue grew 33%, beating analyst expectations
Adjusted EBITDA for Q4 2025 beat analyst expectations
Revenue growth driven by increased orders and higher average order value
Outlook
FIGS expects FY 2026 net revenues growth of 10% to 12%
Company anticipates FY 2026 adjusted EBITDA margin between 12.7% and 12.9%
FIGS sees Q1 2026 revenue growth in the low-20% range
Result Drivers
INCREASED ORDERS - Q4 net revenues rose 33% due to more orders from new and existing customers and higher average order value
GROSS MARGIN PRESSURE - Gross margin fell 440 basis points due to higher tariffs and an inventory write-off, partially offset by lower discount rates and favorable freight rates
OPERATING EXPENSES - Operating expenses increased 16% but fell as a percentage of net revenues due to lower stock-based compensation and fulfillment costs
Company press release: ID:nBw7125hDa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $201.9 mln | $165.32 mln (8 Analysts) |
Q4 Net Income |
| $18.5 mln |
|
Q4 Adjusted EBITDA | Beat | $26.7 mln | $13.67 mln (6 Analysts) |
Q4 Adjusted EBITDA Margin |
| 13.2% |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the apparel & accessories peer group is "buy."
Wall Street's median 12-month price target for Figs Inc is $10.00, about 8.8% below its February 25 closing price of $10.96
The stock recently traded at 91 times the next 12-month earnings vs. a P/E of 91 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.